Optimum’s weekly round-up: From a Knighthood for STORM Therapeutics Limited’s founder Sir Tony Kouzarides, to an €80 million Series B financing!
STORM Therapeutics Ltd., the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, on Monday announced that Tony Kouzarides, PhD, FMedSci, FRS, its Founder & Director and Professor of Cancer Biology, University of Cambridge, will be honoured with a Knighthood for his global impact on disease treatment. Professor Kouzarides, a world leading […]